NEW YORK, March 27 - Isis Pharmaceuticals on Wednesday said that its GeneTrove division will allow Pharmacia to use its antisense inhibitors to validate targets in genes that the biotech company selects.
Pharmacia will also license undisclosed IP from Isis' functional-genomics suite.
Terms of the deal call for Isis to design and deliver antisense inhibitors to Pharmacia. While financial terms of the deal were not disclosed, Isis will maintain the rights to develop antisense drugs to those genes, the company said.
Isis' functional-genomics IP suite comprises approximately 50 patents and applications, a main component of which is RNase H, a naturally occurring cellular enzyme that cleaves the RNA portion of an RNA/DNA duplex.